Significant response of pulmonary sarcomatoid carcinoma with obstructive atelectasis to treatment with the PD-1 inhibitor camrelizumab combined with transbronchial cryoablation: A case report and literature review

Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small cell lung cancer with high malignancy and poor prognosis. Chemotherapy or radiotherapy do not usually provide satisfactory results in patients with PSC, especially in those with advanced-stage cancer. Targeted therapy and immunothe...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 12
Main Authors Nian, Jiayun, Zhu, Yong, Fu, Qi, Yang, Guowang, Wang, Xiaomin
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 27.10.2022
Subjects
camrelizumab
case report
obstructive atelectasis
Oncology
pulmonary sarcomatoid carcinoma
tracheoscopic cryotherapy
Online AccessGet full text

Cover

More Information
Summary:Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small cell lung cancer with high malignancy and poor prognosis. Chemotherapy or radiotherapy do not usually provide satisfactory results in patients with PSC, especially in those with advanced-stage cancer. Targeted therapy and immunotherapy are more precise therapies that may be effective in the treatment of PSC; however, further research is needed. Here, we present a case of stage III PSC with obstructive atelectasis, which is more challenging and hinders treatment. Treatment with the PD-1 inhibitor camrelizumab and transbronchial cryoablation showed significant clinical efficacy. This type of combined treatment has not been reported previously for PSC. Thus, this case may provide a valuable reference for future clinical practice and research.
Bibliography:Edited by: Muhammad Abbas, Riphah International University, Pakistan
Reviewed by: Jing Nie, People’s Liberation Army General Hospital, China; Chunxia Su, Shanghai Pulmonary Hospital, China
This article was submitted to Thoracic Oncology, a section of the journal Frontiers in Oncology
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.1013047